PDCD1 and hepatocellular carcinoma: Even though molecular classification studies suggest that about 35% of HCCs have an immune-reactive TME [33,34] and PD-L1 expression is associated with a worst outcome [35], the activity of anti-PD-1/PD-L1 antibodies in HCC is modest compared with other malignancies.